GlassScriptPhysician profile
Annette Gunsberg
NPI 1285733782
$2,530.47
in general payments reported to CMS, 2019-2025
24 companies · $22.18 in 2025
The $22.18 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $336 · 2021: $309 · 2022: $451 · 2023: $497 · 2024: $562 · 2025: $22.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,081.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $390.85 | 2019-2024 | Jornay Pm |
| Sanofi Pasteur INC. | $381.30 | 2019-2024 | |
| Pfizer INC. | $284.26 | 2019-2025 | |
| Tris Pharma INC | $196.55 | 2019-2024 | Dyanavel Xr, Onyda Xr |
| Corium, LLC | $170.77 | 2022-2024 | Azstarys |
| Palette Life Sciences, INC. | $118.75 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.75 | 2020-2021 | |
| Kaleo, INC. | $102.38 | 2019-2023 | Auvi-Q |
| Nestle Healthcare Nutrition INC. | $89.20 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $87.98 | 2021-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Cranial Technologies, INC | $79.53 | 2021-2024 | Doc Band |
| Ultragenyx Pharmaceutical INC. | $78.34 | 2019-2022 | |
| Verrica Pharmaceuticals INC. | $67.04 | 2023-2024 | Ycanth |
| Supernus Pharmaceuticals, INC. | $64.77 | 2023-2024 | Qelbree, Qelbree |
| Astrazeneca Pharmaceuticals LP | $59.95 | 2023-2024 | Flumist Quadrivalent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $49.46 | 2019 | |
| Aytu Biopharma, INC. | $41.03 | 2020 | |
| Genentech USA, INC. | $32.12 | 2020-2021 | |
| Adlon Therapeutics L.P. | $31.20 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $26.64 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $19.95 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.84 | 2020 | |
| Mylan Pharmaceuticals INC. | $16.92 | 2019 | |
| Neos Therapeutics, LP | $15.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annette Gunsberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.